Viveve Medical (VIVE) 10-Q 8 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 07, 2018
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	879,682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		31,541,439
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 20,097,000	$ 20,730,000	[1]
Accounts receivable, net of allowance for doubtful accounts of $304 and $221 as of September 30, 2018 and December 31, 2017, respectively	4,991,000	6,213,000	[1]
Inventory	4,497,000	2,390,000	[1]
Prepaid expenses and other current assets	2,680,000	2,741,000	[1]
Total current assets	32,265,000	32,074,000	[1]
Property and equipment, net	2,011,000	1,303,000	[1]
Investment in limited liability company	1,961,000	2,500,000	[1]
Other assets	201,000	202,000	[1]
Total assets	36,438,000	36,079,000	[1]
Equity
Common stock, $0.0001 par value; 75,000,000 shares authorized as of September 30, 2018 and December 31, 2017; 31,523,454 and 19,503,558 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively	3,000	2,000	[1]
Additional paid-in capital	139,123,000	102,979,000	[1]
Accumulated deficit	(141,893,000)	(105,581,000)	[1]
Total stockholders’deficit	(2,767,000)	(2,600,000)	[1]
Total liabilities and stockholders’ deficit	36,438,000	36,079,000	[1]
Current liabilities:
Accounts payable	3,562,000	4,799,000	[1]
Accrued liabilities	5,125,000	4,605,000	[1]
Total current liabilities	8,687,000	9,404,000	[1]
Note payable, noncurrent portion	30,124,000	28,948,000	[1]
Other noncurrent liabilities	394,000	327,000	[1]
Total liabilities	39,205,000	38,679,000	[1]
Commitments and contingences (Note 7)
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	[1]
Accounts receivable, allowance for doubtful accounts	$ 304	$ 221
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	31,523,454	19,503,558
Common stock, shares outstanding (in shares)	31,523,454	19,503,558
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue	$ 4,821	$ 4,070	$ 14,045	$ 10,187
Cost of revenue	3,327	2,059	8,390	5,515
Gross profit	1,494	2,011	5,655	4,672
Operating expenses:
Research and development	3,442	3,464	10,870	9,292
Selling, general and administrative	9,114	7,369	27,482	19,681
Total operating expenses	12,556	10,833	38,352	28,973
Loss from operations	(11,062)	(8,822)	(32,697)	(24,301)
Interest expense, net	(1,106)	(777)	(3,239)	(2,385)
Other expense, net	(4)	(16)	(14)	(49)
Net loss from consolidated companies	(12,172)	(9,615)	(35,950)	(26,735)
Loss from minority interest in limited liability company	(132)		(539)
Comprehensive and net loss	$ (12,304)	$ (9,615)	$ (36,489)	$ (26,735)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.39)	$ (0.50)	$ (1.23)	$ (1.59)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	31,490,578	19,408,920	29,568,236	16,843,706

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018		Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (36,489,000)		$ (26,735,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	103,000
Depreciation and amortization	545,000		318,000
Stock-based compensation	2,294,000		1,314,000
Fair value of common stock issued	256,000		260,000
Non-cash interest expense	1,176,000		762,000
Loss from minority interest in limited liability company	539,000
Changes in assets and liabilities:
Accounts receivable	1,119,000		(2,742,000)
Inventory	(2,317,000)		422,000
Prepaid expenses and other current assets	61,000		(2,151,000)
Other noncurrent assets	1,000		24,000
Accounts payable	(1,297,000)		483,000
Accrued and other liabilities	502,000		1,747,000
Other noncurrent liabilities	262,000		24,000
Net cash used in operating activities	(33,245,000)		(26,274,000)
Cash flows from investing activities:
Purchase of property and equipment	(983,000)		(810,000)
Investment in limited liability company			(2,500,000)
Net cash used in investing activities	(983,000)		(3,310,000)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	33,407,000		31,440,000
Proceeds from note payable			19,214,000
Repayments of note payable			(10,000,000)
Proceeds from issuance of common shares from employee stock purchase plan	188,000
Proceeds from exercise of stock options			31,000
Proceeds from exercise of warrant			20,000
Net cash provided by financing activities	33,595,000		40,705,000
Net increase (decrease) in cash and cash equivalents	(633,000)		11,121,000
Cash and cash equivalents - beginning of period	20,730,000	[1]	8,086,000
Cash and cash equivalents - end of period	20,097,000		19,207,000
Supplemental disclosure:
Cash paid for interest	1,991,000		1,619,000
Cash paid for income taxes	2,000
Supplemental disclosure of cash flow information as of end of period:
Issuance of warrants in connection with note payable			940,000
Issuance of note payable in settlement of accrued interest	934,000		285,000
Net transfer of equipment between inventory and property and equipment	$ 210,000		$ 362,000
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s intimate health industry in some countries by marketing the Viveve System as a way to improve the overall well-being and quality of life of women suffering from vaginal introital laxity, for improved sexual function, or stress urinary incontinence, depending on the relevant country-specific clearance or approval. In the United States, the Viveve System is currently indicated for use in general surgical procedures for electrocoagulation and hemostasis. Public Offerings On February 12, 2018, “February 2018 11,500,000 $3.00 $34,500,000. $32,213,000. The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, November 8, 2017, may $25,000,000 “November 2017 three nine September 30, 2018, 3,720 277,249 November 2017 $11,000 $1,194,000. September 30, 2018, 336,498 November 2017 $1,318,000. On March 22, 2017, “March 2017 8,625,000 $4.00 $34,500,000. $31,440,000. Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2017, March 16, 2018. three nine September 30, 2018 not December 31, 2018 Liquidity We expect to continue to meet our operating cash flow requirements through the sales of our products and by raising additional capital from equity or debt financings. We expect that our cash will be sufficient to fund our activities for at least the next six may September 30, 2018, $20,097,000 $23,578,000. September 30, 2018 $141,893,000. may may not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Changes in Accounting Policies Except for the changes for the adoption of the new revenue recognition accounting standard, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard On January 1, 2018, 606 606 606” not January 1, 2018. January 1, 2018 606, not 605 605” Previously under ASC 605, 606, not $177,000, $195,000 $18,000 The details for the impact of the adoption of ASC 606 Balance as of December 31, 2017 Adjustment Due to Adoption of ASC 606 Balance as of January 1, 2018 Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,605 $ 18 (1) $ 4,623 Other noncurrent liabilities $ 327 $ (195 ) (2) $ 132 Equity Accumulated deficit $ (105,581 ) $ 177 (3) $ (105,404 ) ( 1 Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606. ( 2 Change relates to long-term deferred revenue related to the extended warranties not 606. ( 3 Change relates to cumulative effect adjustment upon adoption of ASC 606. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three September 30, 2018, three 42% three September 30, 2017, two 38% nine September 30, 2018, one 21% nine September 30, 2017, three 38% There were no 10% three nine September 30, 2018 2017. As of September 30, 2018, four 64% December 31, 2017, two 57% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $304,000 September 30, 2018 $221,000 December 31, 2017. Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No September 30, 2018 December 31, 2017. $334,000, not September 30, 2018. No December 31, 2017. Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2018, not Contract Costs The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one three nine September 30, 2018, one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated statement of operations for the three nine September 30, 2018 September 30, 2018 For three months ended September 30, 2018 For nine months ended September 30, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Revenue $ 4,821 $ 4,631 $ 190 (1) $ 14,045 $ 13,525 $ 520 (1) Cost of revenue $ 3,327 $ 3,342 $ (15 ) (2) $ 8,390 $ 8,390 $ - (2) Gross profit $ 1,494 $ 1,289 $ 205 (3) $ 5,655 $ 5,135 $ 520 (3) Loss from operations $ (11,062 ) $ (11,267 ) $ 205 (3) $ (32,697 ) $ (33,217 ) $ 520 (3) Comprehensive and net loss $ (12,304 ) $ (12,509 ) $ 205 (3) $ (36,489 ) $ (37,009 ) $ 520 (3) Net loss per share: Basic and diluted $ (0.39 ) $ (0.40 ) $ 0.01 $ (1.23 ) $ (1.25 ) $ 0.02 Weighted average shares 31,490,578 31,490,578 29,568,236 29,568,236 ( 1 Change relates to revenue from extended assurance warranties for which no 606. ( 2 Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606. ( 3 Change relates to the net gain adjustment on the adoption of ASC 606. As of September 30, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheets Liabilities Accrued liabilities $ 5,125 $ 5,259 $ (134 ) (1) Other noncurrent liabilities $ 394 $ 957 $ (563 ) (2) Equity Accumulated deficit $ (141,893 ) $ (142,590 ) $ 697 (3) ( 1 Change relates to future costs associated with extended warranties required to be recorded on the adoption of ASC 606, not 606. ( 2 Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not 606. ( 3 Change relates to $177,000 606 $520,000 nine September 30, 2018. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2018 ( Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 United States $ 3,455 $ 3,277 $ 10,613 $ 7,068 Asia Pacific 717 758 2,238 2,191 Europe and Middle East 612 - 1,143 568 Latin America 37 35 51 360 Total $ 4,821 $ 4,070 $ 14,045 $ 10,187 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments are reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three nine September 30, 2018. Product Warranty The Company’s products are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2018 2017, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Nine Months Ended September 30, 2018 2017 Stock options to purchase common stock 4,298,565 2,489,979 Warrants to purchase common stock 642,622 642,622 Restricted common stock awards 60,000 - Recently Issued and Adopted Accounting Standards In February 2016, 2016 02, 842 July 2018, 2018 10, 842, 2018 11, 842 December 15, 2018, In August 2016, No. 2016 15, 230 zero December 15, 2017, January 1, 2018 not In August 2016, No. 2016 18, 230 December 15, 2017, January 1, 2018 not In May 2017, No. 2017 09, 718 may 718. December 15, 2017, January 1, 2018 not In June 2018, 2018 07, 718 718 718 December 15, 2018, not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no September 30, 2018 December 31, 2017. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of September 30, 2018, December 31, 2017 There were no

Note 4 - Investment in Limited

Note 4 - Investment in Limited Liability Company	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	4. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not September 30, 2018, 3,600 $81,000 $224,000 three nine September 30, 2018, In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not September 30, 2018, 9% three three nine September 30, 2018, $132,000 $539,000,

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued Liabilities Accrued liabilities consisted of the following as of September 30, 2018 December 31, 2017 ( September 30, December 31, 2018 2017 Accrued sales commission $ 1,292 $ 1,067 Accrued bonuses 922 1,597 Accrued interest 676 447 Accrued payroll and other related expenses 527 488 Accrued professional fees 386 562 Customer contracts liabilities 334 - Travel and entertainment 230 156 Accrued sales & use tax 143 149 Accrued clinical trial costs 76 30 Other accruals 539 109 Total accrued liabilities $ 5,125 $ 4,605

Note 6 - Note Payable

Note 6 - Note Payable	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Note Payable On June 20, 2016, January 13, 2017 ( “2016 $10,000,000 two $7,500,000 $2,500,000. $10,000,000 June 20, 2016. 2016 4.00% 2016 May 2017. In connection with the 2016 10 100,402 $4.98 8 On May 22, 2017, “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 2017 may The 2017 six four 2017 12.5%, 4.0% may, three nine September 30, 2018, $318,000 $934,000, September 30, 2018. three nine September 30, 2017, $205,262 $285,000, 5.0% September 30, 2018, $394,000 The Company may 2017 first five no As security for its obligations under the 2017 The terms of the 2017 $2.0 2022, not 2.0 2017 September 30, 2018, In connection with the 2017 two 10 222,049 $9.50 8 As of September 30, 2018, Year Ending December 31, 2018 (remaining three months) $ 683 2019 2,778 2020 2,901 2021 16,672 2022 19,306 Thereafter 6,220 Total payments 48,560 Less: Amount representing interest (17,131 ) Present value of obligations 31,429 Less: Unamortized debt discount (1,305 ) Note payable, noncurrent portion $ 30,124

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Operating Lease On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 Rent expense for the three September 30, 2018 2017 $65,000 $138,000, nine September 30, 2018 2017 $293,000 $305,000, In September 2018, 36 September 20, 2018. $2,600. As of September 30, 2018, Year Ending December 31, 2018 (remaining three months) $ 73 2019 296 2020 143 2021 23 Total minimum lease payments $ 535 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not Legal Proceedings On March 11, 2016, On June 4, 2018, Under the terms of the Settlement Agreement, the Company received an initial monetary payment to settle the litigation and past claims and an on-going royalty for future sales. Viveve granted to ThermiGen a non-exclusive, non-transferable license to use the Company’s U.S. patent for the current version of ThermiGen’s ThermiVa system (which includes RF generators and consumables). The Company has recorded the monetary payment as a gain on litigation settlement in selling, general and administrative expenses on the condensed consolidated statements of operations during the nine September 30, 2018.

Note 8 - Common Stock

Note 8 - Common Stock	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Common Stock On June 8, 2018, 100,000 $2.56 $256,000. On February 12, 2018, February 2018 11,500,000 $3.00 $34,500,000. $32,213,000. Through the November 2017 may $25,000,000 three nine September 30, 2018, 3,720 277,249 November 2017 $10,100 $1,194,000, September 30, 2018, 336,498 November 2017 $1,318,000. Warrants for Common Stock As of September 30, 2018, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622 In connection with the 2016 100,402 $4.98 $350,000. $90,000, May 2017 2017 three nine September 30, 2017, zero $371,000 In connection with the 2017 222,049, $9.50 ten $940,000 0%, 55.1%, 2.25% ten $786,000, three nine September 30, 2018, $82,000 $242,000, three nine September 30, 2017, $68,000 $106,000 September 30, 2018, $1,305,000. No three nine September 30, 2018 2017. No three nine September 30, 2018 2017. The stock-based compensation expense related to warrants issued was zero three nine September 30, 2018 2017.

Note 9 - Summary of Stock Optio

Note 9 - Summary of Stock Options	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of September 30, 2018, 2006 38,378 no $10.49 4.1 On December 6, 2017, 2018 2013 914,016 4,000,000 4,914,016 January 1, 2018. As of September 30, 2018, 2013 4,260,187 378,615 $4.59 8.5 Activity under the 2006 2013 Nine Months Ended September 30, 2018 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 2,694,224 $ 5.80 8.6 $ 249,154 Options granted 2,271,059 $ 3.54 Options exercised - $ - Options canceled (666,718 ) $ 5.55 Options outstanding, end of period 4,298,565 $ 4.64 8.5 $ 432,450 Vested and exercisable and expected to vest, end of period 4,047,441 $ 4.68 8.4 $ 395,182 Vested and exercisable, end of period 1,406,846 $ 5.56 7.1 $ 22,615 The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of September 30, 2018. The options outstanding and exercisable as of September 30, 2018 Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Price Sept 30, 2018 Price Term (Years) Sept 30, 2018 Price $1.75 - $1.97 535,000 $ 1.95 9.6 31,250 $ 1.97 $2.02 - $2.83 167,500 $ 2.45 9.6 10,678 $ 2.64 $3.11 - $3.82 481,876 $ 3.56 9.3 59,910 $ 3.76 $4.30 - $4.97 1,435,464 $ 4.53 8.7 406,550 $ 4.63 $5.01 - $5.67 771,655 $ 5.35 8.1 326,006 $ 5.35 $6.00 - $6.61 551,058 $ 6.04 7.0 371,812 $ 6.02 $7.00 - $7.92 317,634 $ 7.66 7.5 162,262 $ 7.67 $9.92 38,135 $ 9.92 4.1 38,135 $ 9.92 $59.60 - $149.04 243 $ 100.46 2.2 243 $ 100.46 4,298,565 $ 4.64 8.5 1,406,846 $ 5.56 Stock Option Modifications On May 30, 2018, December 31, 2018. May 30, 2018, six three one $97,000 Restricted Stock Awards In July 2018, 18,278 2013 $2.63 18,278 In June 2018, 50,000 $3.58 two September 30, 2018, zero In April 2018, 14,672 2013 $3.44 14,672 In January 2018, 9,637 2013 $5.19 9,637 In January 2018, 25,000 $5.19 one September 30, 2018, 25,000 As of September 30, 2018, 60,000 2017 The second 2017 “2017 January 1, 2018 March 31, 2018, 20,744 March 29, 2018 $3.11. third 2017 April 1, 2018 June 30, 2018, 25,618 June 29, 2018 $2.31. fourth 2017 July 1, 2018 September 30, 2018, 28,698 September 28, 2018 $2.24. As of September 30, 2018, 2017 307,046 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Three Months Ended Nine Months Ended September 30, 2018 September 30, 2018 Expected term (in years) 0.25 0.25 Average volatility 67% 67% Risk-free interest rate 1.93% 1.71% Dividend yield 0% 0% The weighted average grant date fair value of the purchase rights issued under the 2017 three nine September 30, 2018 $0.75 $1.00, Stock-Based Compensation During the three September 30, 2018 2017, 237,500 305,000 $3.01 $3.91 nine September 30, 2018 2017, 2,058,671 720,110 $3.65 $2.83 no three nine September 30, 2018. 7,730 nine September 30, 2017. nine September 30, 2017 $31,000. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Expected term (in years) 5 5 5 5 Average volatility 70% 64% 73% 55% Risk-free interest rate 2.86% 1.73% 2.67% 1.83% Dividend yield 0% 0% 0% 0% During the three nine September 30, 2018, 10,000 212,388 $2.83 $2.42, three nine September 30, 2017, 14,000 19,875 $3.66 $4.09, no three nine September 30, 2018 2017. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Expected term (in years) 10 10 10 10 Average volatility 66% 78% 66% 78% Risk-free interest rate 3.04% 2.32% 3.04% 2.31% Dividend yield 0% 0% 0% 0% Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three nine September 30, 2018 2017 Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Cost of revenue $ 19 $ 5 $ 47 $ 12 Research and development 79 62 266 170 Selling, general and administrative 667 420 1,981 1,132 Total $ 765 $ 487 $ 2,294 $ 1,314 As of September 30, 2018, $5,604,000. 2.87

Note 10 - Income Taxes

Note 10 - Income Taxes	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% three nine September 30, 2018 2017. 2018 0%. On December 22, 2017, 21%, January 1, 2018. The Company is required to recognize the effect on deferred tax assets and liabilities due to a change in tax rates in the period the tax rate change was enacted. The carrying value of the Company’s U.S. deferred taxes is determined by the enacted U.S. corporate income tax rate. Consequently, the reduction in the U.S. corporate income tax rate impacts the carrying value of our deferred tax assets. Under the new corporate income tax rate of 21%, not

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. Related Party Transactions In June 2006, October 4, 2007. 300 September 30, 2018, 792 37,500 $3,015,000 $2,620,000 three September 30, 2018 2017, $8,613,000 $6,326,000 nine September 30, 2018 2017, September 30, 2018 December 31, 2017 $1,162,000 $1,380,000, In connection with the Distributorship Agreement entered into with ICM in August 2017, $2,500,000 September 30, 2018, 3,850 $81,000 $224,000 three nine September 30, 2018, September 30, 2018 December 31, 2017 $27,000 $28,000,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Changes in Accounting Policies, Policy [Policy Text Block]	Changes in Accounting Policies Except for the changes for the adoption of the new revenue recognition accounting standard, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard On January 1, 2018, 606 606 606” not January 1, 2018. January 1, 2018 606, not 605 605” Previously under ASC 605, 606, not $177,000, $195,000 $18,000 The details for the impact of the adoption of ASC 606 Balance as of December 31, 2017 Adjustment Due to Adoption of ASC 606 Balance as of January 1, 2018 Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,605 $ 18 (1) $ 4,623 Other noncurrent liabilities $ 327 $ (195 ) (2) $ 132 Equity Accumulated deficit $ (105,581 ) $ 177 (3) $ (105,404 ) ( 1 Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606. ( 2 Change relates to long-term deferred revenue related to the extended warranties not 606. ( 3 Change relates to cumulative effect adjustment upon adoption of ASC 606.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three September 30, 2018, three 42% three September 30, 2017, two 38% nine September 30, 2018, one 21% nine September 30, 2017, three 38% There were no 10% three nine September 30, 2018 2017. As of September 30, 2018, four 64% December 31, 2017, two 57%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $304,000 September 30, 2018 $221,000 December 31, 2017.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No September 30, 2018 December 31, 2017. $334,000, not September 30, 2018. No December 31, 2017. Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2018, not Contract Costs The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one three nine September 30, 2018, one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated statement of operations for the three nine September 30, 2018 September 30, 2018 For three months ended September 30, 2018 For nine months ended September 30, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Revenue $ 4,821 $ 4,631 $ 190 (1) $ 14,045 $ 13,525 $ 520 (1) Cost of revenue $ 3,327 $ 3,342 $ (15 ) (2) $ 8,390 $ 8,390 $ - (2) Gross profit $ 1,494 $ 1,289 $ 205 (3) $ 5,655 $ 5,135 $ 520 (3) Loss from operations $ (11,062 ) $ (11,267 ) $ 205 (3) $ (32,697 ) $ (33,217 ) $ 520 (3) Comprehensive and net loss $ (12,304 ) $ (12,509 ) $ 205 (3) $ (36,489 ) $ (37,009 ) $ 520 (3) Net loss per share: Basic and diluted $ (0.39 ) $ (0.40 ) $ 0.01 $ (1.23 ) $ (1.25 ) $ 0.02 Weighted average shares 31,490,578 31,490,578 29,568,236 29,568,236 ( 1 Change relates to revenue from extended assurance warranties for which no 606. ( 2 Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606. ( 3 Change relates to the net gain adjustment on the adoption of ASC 606. As of September 30, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheets Liabilities Accrued liabilities $ 5,125 $ 5,259 $ (134 ) (1) Other noncurrent liabilities $ 394 $ 957 $ (563 ) (2) Equity Accumulated deficit $ (141,893 ) $ (142,590 ) $ 697 (3) ( 1 Change relates to future costs associated with extended warranties required to be recorded on the adoption of ASC 606, not 606. ( 2 Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not 606. ( 3 Change relates to $177,000 606 $520,000 nine September 30, 2018. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2018 ( Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 United States $ 3,455 $ 3,277 $ 10,613 $ 7,068 Asia Pacific 717 758 2,238 2,191 Europe and Middle East 612 - 1,143 568 Latin America 37 35 51 360 Total $ 4,821 $ 4,070 $ 14,045 $ 10,187 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments are reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three nine September 30, 2018.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to warranties between one three not
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2018 2017,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Nine Months Ended September 30, 2018 2017 Stock options to purchase common stock 4,298,565 2,489,979 Warrants to purchase common stock 642,622 642,622 Restricted common stock awards 60,000 -
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In February 2016, 2016 02, 842 July 2018, 2018 10, 842, 2018 11, 842 December 15, 2018, In August 2016, No. 2016 15, 230 zero December 15, 2017, January 1, 2018 not In August 2016, No. 2016 18, 230 December 15, 2017, January 1, 2018 not In May 2017, No. 2017 09, 718 may 718. December 15, 2017, January 1, 2018 not In June 2018, 2018 07, 718 718 718 December 15, 2018, not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Cumulative Effect of Adjustments for New Accounting Pronouncements on Balance Sheet [Table Text Block]	Balance as of December 31, 2017 Adjustment Due to Adoption of ASC 606 Balance as of January 1, 2018 Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,605 $ 18 (1) $ 4,623 Other noncurrent liabilities $ 327 $ (195 ) (2) $ 132 Equity Accumulated deficit $ (105,581 ) $ 177 (3) $ (105,404 )
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	For three months ended September 30, 2018 For nine months ended September 30, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Revenue $ 4,821 $ 4,631 $ 190 (1) $ 14,045 $ 13,525 $ 520 (1) Cost of revenue $ 3,327 $ 3,342 $ (15 ) (2) $ 8,390 $ 8,390 $ - (2) Gross profit $ 1,494 $ 1,289 $ 205 (3) $ 5,655 $ 5,135 $ 520 (3) Loss from operations $ (11,062 ) $ (11,267 ) $ 205 (3) $ (32,697 ) $ (33,217 ) $ 520 (3) Comprehensive and net loss $ (12,304 ) $ (12,509 ) $ 205 (3) $ (36,489 ) $ (37,009 ) $ 520 (3) Net loss per share: Basic and diluted $ (0.39 ) $ (0.40 ) $ 0.01 $ (1.23 ) $ (1.25 ) $ 0.02 Weighted average shares 31,490,578 31,490,578 29,568,236 29,568,236 As of September 30, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheets Liabilities Accrued liabilities $ 5,125 $ 5,259 $ (134 ) (1) Other noncurrent liabilities $ 394 $ 957 $ (563 ) (2) Equity Accumulated deficit $ (141,893 ) $ (142,590 ) $ 697 (3)
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 United States $ 3,455 $ 3,277 $ 10,613 $ 7,068 Asia Pacific 717 758 2,238 2,191 Europe and Middle East 612 - 1,143 568 Latin America 37 35 51 360 Total $ 4,821 $ 4,070 $ 14,045 $ 10,187
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Nine Months Ended September 30, 2018 2017 Stock options to purchase common stock 4,298,565 2,489,979 Warrants to purchase common stock 642,622 642,622 Restricted common stock awards 60,000 -

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2018 2017 Accrued sales commission $ 1,292 $ 1,067 Accrued bonuses 922 1,597 Accrued interest 676 447 Accrued payroll and other related expenses 527 488 Accrued professional fees 386 562 Customer contracts liabilities 334 - Travel and entertainment 230 156 Accrued sales & use tax 143 149 Accrued clinical trial costs 76 30 Other accruals 539 109 Total accrued liabilities $ 5,125 $ 4,605

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2018 (remaining three months) $ 683 2019 2,778 2020 2,901 2021 16,672 2022 19,306 Thereafter 6,220 Total payments 48,560 Less: Amount representing interest (17,131 ) Present value of obligations 31,429 Less: Unamortized debt discount (1,305 ) Note payable, noncurrent portion $ 30,124

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2018 (remaining three months) $ 73 2019 296 2020 143 2021 23 Total minimum lease payments $ 535

Note 8 - Common Stock (Tables)

Note 8 - Common Stock (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622

Note 9 - Summary of Stock Opt_2

Note 9 - Summary of Stock Options (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Nine Months Ended September 30, 2018 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 2,694,224 $ 5.80 8.6 $ 249,154 Options granted 2,271,059 $ 3.54 Options exercised - $ - Options canceled (666,718 ) $ 5.55 Options outstanding, end of period 4,298,565 $ 4.64 8.5 $ 432,450 Vested and exercisable and expected to vest, end of period 4,047,441 $ 4.68 8.4 $ 395,182 Vested and exercisable, end of period 1,406,846 $ 5.56 7.1 $ 22,615
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Price Sept 30, 2018 Price Term (Years) Sept 30, 2018 Price $1.75 - $1.97 535,000 $ 1.95 9.6 31,250 $ 1.97 $2.02 - $2.83 167,500 $ 2.45 9.6 10,678 $ 2.64 $3.11 - $3.82 481,876 $ 3.56 9.3 59,910 $ 3.76 $4.30 - $4.97 1,435,464 $ 4.53 8.7 406,550 $ 4.63 $5.01 - $5.67 771,655 $ 5.35 8.1 326,006 $ 5.35 $6.00 - $6.61 551,058 $ 6.04 7.0 371,812 $ 6.02 $7.00 - $7.92 317,634 $ 7.66 7.5 162,262 $ 7.67 $9.92 38,135 $ 9.92 4.1 38,135 $ 9.92 $59.60 - $149.04 243 $ 100.46 2.2 243 $ 100.46 4,298,565 $ 4.64 8.5 1,406,846 $ 5.56
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Expected term (in years) 5 5 5 5 Average volatility 70% 64% 73% 55% Risk-free interest rate 2.86% 1.73% 2.67% 1.83% Dividend yield 0% 0% 0% 0% Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Expected term (in years) 10 10 10 10 Average volatility 66% 78% 66% 78% Risk-free interest rate 3.04% 2.32% 3.04% 2.31% Dividend yield 0% 0% 0% 0%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Cost of revenue $ 19 $ 5 $ 47 $ 12 Research and development 79 62 266 170 Selling, general and administrative 667 420 1,981 1,132 Total $ 765 $ 487 $ 2,294 $ 1,314
2017 Employee Stock Purchase Plan [Member]
Notes Tables
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, 2018 September 30, 2018 Expected term (in years) 0.25 0.25 Average volatility 67% 67% Risk-free interest rate 1.93% 1.71% Dividend yield 0% 0%

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Feb. 12, 2018	Nov. 08, 2017	Mar. 22, 2017	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017	[1]	Dec. 31, 2016
Proceeds from Issuance of Common Stock					$ 33,407,000	$ 31,440,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance				$ 20,097,000	20,097,000	$ 19,207,000	$ 20,097,000		$ 20,730,000		$ 8,086,000
Working Capital				23,578,000	23,578,000		23,578,000
Retained Earnings (Accumulated Deficit), Ending Balance				$ (141,893,000)	$ (141,893,000)		$ (141,893,000)	$ (105,404,000)	$ (105,581,000)
February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	11,500,000
Share Price	$ 3
Proceeds from Issuance of Common Stock	$ 34,500,000
Proceeds From Issuance of Common Stock, Net	$ 32,213,000
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues				3,720	277,249		336,498
Proceeds From Issuance of Common Stock, Net				$ 10,100	$ 1,194,000		$ 1,318,000
Aggregate Offering Price		$ 25,000,000
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues			8,625,000
Share Price			$ 4
Proceeds from Issuance of Common Stock			$ 34,500,000
Proceeds From Issuance of Common Stock, Net			$ 31,440,000
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)		3 Months Ended		9 Months Ended		12 Months Ended
		Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)		Jan. 01, 2018USD ($)
Retained Earnings (Accumulated Deficit), Ending Balance		$ (141,893,000)		$ (141,893,000)		$ (105,581,000)	[1]	$ (105,404,000)
Other Liabilities, Noncurrent, Total		394,000		394,000		327,000	[1]	132,000
Accrued Liabilities, Current, Total		$ 5,125,000		$ 5,125,000		4,605,000	[1]	4,623,000
Number of Financial Institutions		1		1
Allowance for Doubtful Accounts Receivable, Ending Balance		$ 304,000		$ 304,000		221,000
Contract with Customer, Asset, Net, Total		0		0		0
Contract with Customer, Liability, Total		334,000		334,000		$ 0
Gross Profit, Total		1,494,000	$ 2,011,000	5,655,000	$ 4,672,000
Equity Method Investment, Other than Temporary Impairment		$ 0		$ 0
Minimum [Member]
Warranty Period		1 year
Maximum [Member]
Warranty Period				3 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Number of Customers		3	2	1	3
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Three Customers [Member]
Concentration Risk, Percentage		42.00%			38.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Two Customers [Member]
Concentration Risk, Percentage			38.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | One Customer [Member]
Concentration Risk, Percentage				21.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers				4		2
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage				64.00%		57.00%
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance	[2]							177,000
Other Liabilities, Noncurrent, Total	[3]							(195,000)
Accrued Liabilities, Current, Total	[4]							$ 18,000
Gross Profit, Total				$ 520,000
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.
[2]	Change relates to cumulative effect adjustment upon adoption of ASC 606.
[3]	Change relates to long-term deferred revenue related to the extended warranties not required to be recorded under ASC 606.
[4]	Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606.

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Cumulative Effect of Adjustments for New Accounting Pronouncements on Consolidated Balance Sheet (Details) - USD ($)		Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017	[1]
Liabilities
Accrued liabilities		$ 5,125,000	$ 4,623,000	$ 4,605,000
Other noncurrent liabilities		394,000	132,000	327,000
Equity
Accumulated deficit		$ (141,893,000)	(105,404,000)	$ (105,581,000)
Accounting Standards Update 2014-09 [Member]
Liabilities
Accrued liabilities	[2]		18,000
Other noncurrent liabilities	[3]		(195,000)
Equity
Accumulated deficit	[4]		$ 177,000
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.
[2]	Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606.
[3]	Change relates to long-term deferred revenue related to the extended warranties not required to be recorded under ASC 606.
[4]	Change relates to cumulative effect adjustment upon adoption of ASC 606.

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Impact of New Standard on Consolidated Balance Sheet and Consolidated Statements of Operations (Details) - USD ($)		3 Months Ended			9 Months Ended
		Sep. 30, 2018		Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017	[1]
Revenue		$ 4,821,000		$ 4,070,000	$ 14,045,000	$ 10,187,000
Cost of revenue		3,327,000		2,059,000	8,390,000	5,515,000
Gross profit		1,494,000		2,011,000	5,655,000	4,672,000
Loss from operations		(11,062,000)		(8,822,000)	(32,697,000)	(24,301,000)
Comprehensive and net loss		$ (12,304,000)		$ (9,615,000)	$ (36,489,000)	$ (26,735,000)
Basic and diluted (in dollars per share)		$ (0.39)		$ (0.50)	$ (1.23)	$ (1.59)
Weighted average shares (in shares)		31,490,578		19,408,920	29,568,236	16,843,706
Liabilities
Accrued liabilities		$ 5,125,000			$ 5,125,000		$ 4,623,000	$ 4,605,000
Other noncurrent liabilities		394,000			394,000		132,000	327,000
Equity
Accumulated deficit		(141,893,000)			(141,893,000)		(105,404,000)	$ (105,581,000)
Accounting Standards Update 2014-09 [Member]
Gross profit					520,000
Liabilities
Accrued liabilities	[2]						18,000
Other noncurrent liabilities	[3]						(195,000)
Equity
Accumulated deficit	[4]						$ 177,000
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenue		4,631,000			13,525,000
Cost of revenue		3,342,000			8,390,000
Gross profit		1,289,000			5,135,000
Loss from operations		(11,267,000)			(33,217,000)
Comprehensive and net loss		$ (12,509,000)			$ (37,009,000)
Basic and diluted (in dollars per share)		$ (0.40)			$ (1.25)
Weighted average shares (in shares)		31,490,578			29,568,236
Liabilities
Accrued liabilities		$ 5,259,000			$ 5,259,000
Other noncurrent liabilities		957,000			957,000
Equity
Accumulated deficit		(142,590,000)			(142,590,000)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenue		190,000	[5]		520,000
Cost of revenue		(15,000)	[6]
Gross profit		205,000	[7]		520,000
Loss from operations		205,000	[7]		520,000
Comprehensive and net loss		$ 205,000	[7]		$ 520,000
Basic and diluted (in dollars per share)		$ 0.01	[7]		$ 0.02
Weighted average shares (in shares)
Liabilities
Accrued liabilities	[8]	$ (134,000)			$ (134,000)
Other noncurrent liabilities	[9]	(563,000)			(563,000)
Equity
Accumulated deficit	[10]	$ 697,000			$ 697,000
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.
[2]	Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606.
[3]	Change relates to long-term deferred revenue related to the extended warranties not required to be recorded under ASC 606.
[4]	Change relates to cumulative effect adjustment upon adoption of ASC 606.
[5]	Change relates to revenue from extended assurance warranties for which no deferral is required on the adoption of ASC 606.
[6]	Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606.
[7]	Change relates to the net gain adjustment on the adoption of ASC 606.
[8]	Change relates to future costs associated with extended warranties required to be recorded on the adoption of ASC 606, partially offset by the current portion of deferred revenue in connection with the extended warranties not required to be recorded under ASC 606.
[9]	Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not required to be recorded under ASC 606.
[10]	Change relates to $177,000 cumulative effect adjustment on the adoption of ASC 606 and the net gain adjustment of $520,000 for the nine months ended September 30, 2018.

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue	$ 4,821	$ 4,070	$ 14,045	$ 10,187
UNITED STATES
Revenue	3,455	3,277	10,613	7,068
Asia Pacific [Member]
Revenue	717	758	2,238	2,191
Europe And Middle East [Member]
Revenue	612		1,143	568
Latin America [Member]
Revenue	$ 37	$ 35	$ 51	$ 360

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Employee Stock Option [Member]
Stock options to purchase common stock (in shares)	4,298,565	2,489,979
Common Stock Warrants [Member]
Stock options to purchase common stock (in shares)	642,622	642,622
Restricted Stock [Member]
Stock options to purchase common stock (in shares)	60,000

Note 4 - Investment in Limite_2

Note 4 - Investment in Limited Liability Company (Details Textual) - USD ($)	Aug. 08, 2017	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018
Payments to Acquire Equity Method Investments				$ 2,500,000
Income (Loss) from Equity Method Investments, Total			$ (539,000)
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		9.00%	9.00%		9.00%
Income (Loss) from Equity Method Investments, Total		$ (132,000)	$ (539,000)
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Payments for Purchase of Products		$ 81,000			$ 224,000
Payments to Acquire Equity Method Investments	$ 2,500,000		$ 2,500,000

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Accrued sales commission	$ 1,292		$ 1,067
Accrued bonuses	922		1,597
Accrued interest	676		447
Accrued payroll and other related expenses	527		488
Accrued professional fees	386		562
Customer contracts liabilities	334
Travel and entertainment	230		156
Accrued sales & use tax	143		149
Accrued clinical trial costs	76		30
Other accruals	539		109
Total accrued liabilities	$ 5,125	$ 4,623	$ 4,605	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - USD ($)	May 22, 2017	Jun. 20, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			642,622		642,622
Interest Payable			$ 17,131,000		$ 17,131,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Warrant Term		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		100,402	100,402		100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.98	$ 4.98		$ 4.98
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,049		222,049		222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.50		$ 9.50		$ 9.50
Warrants and Rights Outstanding, Term	10 years
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member]
Debt Instrument, Face Amount		$ 10,000,000
Debt Instrument, Fee, Percentage		4.00%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | First Tranche [Member]
Proceeds from Issuance of Long-term Debt, Total		$ 7,500,000
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Second Tranche [Member]
Proceeds from Issuance of Long-term Debt, Total		$ 2,500,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount	$ 20,000,000
Debt Agreement, Covenant, Additional Funding	10,000,000
Debt Agreement, Maximum Borrowing Capacity	$ 30,000,000
Debt Instrument, Term	6 years
Debt instrument, Interest Only Payment, Period	4 years
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period	4.00%
Paid-in-Kind Interest			$ 318,000	$ 205,262	$ 934,000	$ 285,000
Debt Instrument, Prepayment Fee, Percentage	5.00%
Debt Instrument, Prepayment Fee, Period of Term	5 years
Debt Instrument, Covenant, Cash and Cash Equivalents	$ 2,000,000
The 2017 Loan Agreement [Member] | CRG LP [Member] | Other Noncurrent Liabilities [Member]
Interest Payable			$ 394,000		$ 394,000

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	[1]
2018 (remaining three months)	$ 683
2,019	2,778
2,020	2,901
2,021	16,672
2,022	19,306
Thereafter	6,220
Total payments	48,560
Less: Amount representing interest	(17,131)
Present value of obligations	31,429
Less: Unamortized debt discount	(1,305)
Note payable, noncurrent portion	$ 30,124	$ 28,948
[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Commitments and Cont_3

Note 7 - Commitments and Contingencies (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Feb. 01, 2017USD ($)ft²$ / item
Operating Leases, Rent Expense, Total		$ 65,000	$ 138,000	$ 293,000	$ 305,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | ft²						12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | $ / item						20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | $ / item						21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | $ / item						21.75
Security Deposit						$ 22,000
Operating Leases, Allowance for Certain Improvements						$ 88,000
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract	3 years	3 years		3 years
Operating Leases, Monthly Payment	$ 2,600

Note 7 - Commitments and Cont_4

Note 7 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2018USD ($)
2018 (remaining three months)	$ 73
2,019	296
2,020	143
2,021	23
Total minimum lease payments	$ 535

Note 8 - Common Stock (Details

Note 8 - Common Stock (Details Textual)	Jun. 08, 2018USD ($)$ / sharesshares	Feb. 12, 2018USD ($)$ / sharesshares	Nov. 08, 2017USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)shares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)shares	Sep. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)	May 22, 2017USD ($)yr$ / sharesshares	Jun. 20, 2016USD ($)$ / sharesshares
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares	100,000
Shares Issued, Price Per Share | $ / shares	$ 2.56
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 256,000
Proceeds from Issuance of Common Stock						$ 33,407,000	$ 31,440,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				642,622		642,622		642,622
Amortization of Debt Discount (Premium)					$ 0
Debt Instrument, Unamortized Discount, Total				$ 1,305,000		$ 1,305,000		$ 1,305,000
Class of Warrants or Rights, Exercises in Period | shares				0	0	0	0
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period | shares				0	0	0	0
Allocated Share-based Compensation Expense, Total				$ 765,000	$ 487,000	$ 2,294,000	$ 1,314,000
The 2016 Loan Agreement [Member]
Debt Issuance Costs, Net, Total											$ 90,000
Amortization of Debt Discount (Premium)							371,000
The 2017 Loan Agreement [Member]
Debt Issuance Costs, Net, Total									$ 786,000
Amortization of Debt Discount (Premium)				$ 82,000	68,000	$ 242,000	106,000
Debt Instrument, Unamortized Discount, Total					1,305,000		1,305,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				100,402		100,402		100,402			100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 4.98		$ 4.98		$ 4.98			$ 4.98
Warrants and Rights Outstanding											$ 350,000
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				222,049		222,049		222,049		222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 9.50		$ 9.50		$ 9.50		$ 9.50
Warrants and Rights Outstanding										$ 940,000
Warrants and Rights Outstanding, Term										10 years
Allocated Share-based Compensation Expense, Total				$ 0	$ 0	$ 0	$ 0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input										0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input										0.551
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input										0.0225
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr										10
February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues | shares		11,500,000
Share Price | $ / shares		$ 3
Proceeds from Issuance of Common Stock		$ 34,500,000
Proceeds From Issuance of Common Stock, Net		$ 32,213,000
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues | shares				3,720		277,249		336,498
Proceeds From Issuance of Common Stock, Net				$ 10,100		$ 1,194,000		$ 1,318,000
Aggregate Offering Price			$ 25,000,000

Note 8 - Common Stock - Summary

Note 8 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2018	May 22, 2017	Jun. 20, 2016
Shares Outstanding Under Warrants (in shares)	642,622
September 2014 Issuance Through Private Offering [Member]
Expiration Date	Sep. 23, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	86,831
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	29,000
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	12,500
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 4
Shares Outstanding Under Warrants (in shares)	75,697
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 2.72
Shares Outstanding Under Warrants (in shares)	1,454
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	36,229
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	21,585
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 5.60
Shares Outstanding Under Warrants (in shares)	26,875
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 6.08
Shares Outstanding Under Warrants (in shares)	25,000
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 7.74
Shares Outstanding Under Warrants (in shares)	5,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 4.98		$ 4.98
Shares Outstanding Under Warrants (in shares)	100,402		100,402
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 9.50	$ 9.50
Shares Outstanding Under Warrants (in shares)	222,049	222,049

Note 9 - Summary of Stock Opt_3

Note 9 - Summary of Stock Options (Details Textual) - USD ($)	Sep. 28, 2018	Jun. 29, 2018	May 30, 2018	Mar. 29, 2018	Dec. 06, 2017	Jul. 31, 2018	Jun. 30, 2018	Apr. 30, 2018	Jan. 31, 2018	Sep. 30, 2018	Sep. 28, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 28, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 05, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance										4,298,565					4,298,565			2,694,224
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance										$ 4.64					$ 4.64			$ 5.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term															8 years 182 days			8 years 219 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															2,271,059
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value																	$ 31,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate										0.00%			0.00%		0.00%		0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options										$ 5,604,000					$ 5,604,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition															2 years 317 days
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate										0.00%			0.00%		0.00%		0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost			$ 97,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate															0.00%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance										60,000					60,000
Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period							50,000		25,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 3.58		$ 5.19
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period							0								25,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							2 years		1 year
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance										38,378					38,378
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										0					0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance										$ 10.49					$ 10.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term															4 years 36 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance										4,260,187					4,260,187
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance										$ 4.59					$ 4.59
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term															8 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized					914,016
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					4,914,016														4,000,000
Common Stock, Capital Shares Reserved for Future Issuance										378,615					378,615
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										237,500			305,000		2,058,671		720,110
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value										$ 3.01			$ 3.91		$ 3.65		$ 2.83
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										0					0		7,730
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										10,000			14,000		212,388		19,875
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value										$ 2.83			$ 3.66		$ 2.42		$ 4.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										0			0		0		0
The 2013 Plan [Member] | Restricted Stock [Member] | Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period						18,278		14,672	9,637
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value						$ 2.63		$ 3.44	$ 5.19
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period						18,278		14,672	9,637
2017 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value											$ 0.75					$ 1
Stock Issued During Period, Shares, Employee Stock Purchase Plans	28,698	25,618		20,744
Employee Stock Purchase Plan, Purchase Price	$ 2.24	$ 2.31		$ 3.11							$ 2.24					$ 2.24
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares										307,046					307,046
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate												0.00%		0.00%

Note 9 - Summary of Stock Opt_4

Note 9 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares
Options outstanding, Shares (in shares) | shares	2,694,224
Options outstanding, Weighted average exercise price (in dollars per share) | $ / shares	$ 5.80
Options outstanding, Weighted Average Remaining Contractual Term (Year)	8 years 182 days	8 years 219 days
Options outstanding, Aggregate Intrinsic Value | $	$ 432,450	$ 249,154
Options granted, Shares (in shares) | shares	2,271,059
Options granted, Weighted average exercise price (in dollars per share) | $ / shares	$ 3.54
Options exercised, Shares (in shares) | shares
Options exercised, Weighted average exercise price (in dollars per share) | $ / shares
Options canceled, Shares (in shares) | shares	(666,718)
Options canceled, Weighted average exercise price (in dollars per share) | $ / shares	$ 5.55
Options outstanding, Shares (in shares) | shares	4,298,565	2,694,224
Options outstanding, Weighted average exercise price (in dollars per share) | $ / shares	$ 4.64	$ 5.80
Vested and exercisable and expected to vest, end of period, Number Of Shares (in shares) | shares	4,047,441
Vested and exercisable and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 4.68
Vested and exercisable and expected to vest, end of period, Weighted Average Remaining Contractual Term (Year)	8 years 146 days
Vested and exercisable and expected to vest, end of period, Aggregate Intrinsic Value | $	$ 395,182
Vested and exercisable, end of period, Number Of Shares (in shares) | shares	1,406,846
Vested and exercisable, end of period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 5.56
Vested and exercisable, end of period, Weighted Average Remaining Contractual Term (Year)	7 years 36 days
Vested and exercisable, end of period, Aggregate Intrinsic Value | $	$ 22,615

Note 9 - Summary of Stock Opt_5

Note 9 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Exercise price range, upper limit (in dollars per share)	$ 2.64
Options outstanding, number (in shares) | shares	4,298,565
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.64
Options outstanding, weighted average remaining contractual term (Year)	8 years 182 days
Options exercisable, number exercisable (in shares) | shares	1,406,846
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.56
Range One [Member]
Exercise price range, lower limit (in dollars per share)	1.75
Exercise price range, upper limit (in dollars per share)	$ 1.97
Options outstanding, number (in shares) | shares	535,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.95
Options outstanding, weighted average remaining contractual term (Year)	9 years 219 days
Options exercisable, number exercisable (in shares) | shares	31,250
Options exercisable, weighted average exercise price (in dollars per share)	$ 1.97
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	2.02
Exercise price range, upper limit (in dollars per share)	$ 2.83
Options outstanding, number (in shares) | shares	167,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.45
Options outstanding, weighted average remaining contractual term (Year)	9 years 219 days
Options exercisable, number exercisable (in shares) | shares	10,678
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.64
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	3.11
Exercise price range, upper limit (in dollars per share)	$ 3.82
Options outstanding, number (in shares) | shares	481,876
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.56
Options outstanding, weighted average remaining contractual term (Year)	9 years 109 days
Options exercisable, number exercisable (in shares) | shares	59,910
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.76
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	4.30
Exercise price range, upper limit (in dollars per share)	$ 4.97
Options outstanding, number (in shares) | shares	1,435,464
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.53
Options outstanding, weighted average remaining contractual term (Year)	8 years 255 days
Options exercisable, number exercisable (in shares) | shares	406,550
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.63
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	5.01
Exercise price range, upper limit (in dollars per share)	$ 5.67
Options outstanding, number (in shares) | shares	771,655
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.35
Options outstanding, weighted average remaining contractual term (Year)	8 years 36 days
Options exercisable, number exercisable (in shares) | shares	326,006
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.35
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	6
Exercise price range, upper limit (in dollars per share)	$ 6.61
Options outstanding, number (in shares) | shares	551,058
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.04
Options outstanding, weighted average remaining contractual term (Year)	7 years
Options exercisable, number exercisable (in shares) | shares	371,812
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.02
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	7
Exercise price range, upper limit (in dollars per share)	$ 7.92
Options outstanding, number (in shares) | shares	317,634
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.66
Options outstanding, weighted average remaining contractual term (Year)	7 years 182 days
Options exercisable, number exercisable (in shares) | shares	162,262
Options exercisable, weighted average exercise price (in dollars per share)	$ 7.67
Range Eight [Member]
Options outstanding, number (in shares) | shares	38,135
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.92
Options outstanding, weighted average remaining contractual term (Year)	4 years 36 days
Options exercisable, number exercisable (in shares) | shares	38,135
Options exercisable, weighted average exercise price (in dollars per share)	$ 9.92
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	59.60
Exercise price range, upper limit (in dollars per share)	$ 149.04
Options outstanding, number (in shares) | shares	243
Options outstanding, weighted average exercise price (in dollars per share)	$ 100.46
Options outstanding, weighted average remaining contractual term (Year)	2 years 73 days
Options exercisable, number exercisable (in shares) | shares	243
Options exercisable, weighted average exercise price (in dollars per share)	$ 100.46

Note 9 - Summary of Stock Opt_6

Note 9 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Expected term (Year)	5 years		5 years		5 years	5 years
Average volatility	70.00%		64.00%		73.00%	55.00%
Risk-free interest rate	2.86%		1.73%		2.67%	1.83%
Dividend yield	0.00%		0.00%		0.00%	0.00%
2017 Employee Stock Purchase Plan [Member]
Expected term (Year)		91 days		91 days
Average volatility		67.00%		67.00%
Risk-free interest rate		1.93%		1.71%
Dividend yield		0.00%		0.00%

Note 9 - Summary of Stock Opt_7

Note 9 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Expected term (Year)	5 years	5 years	5 years	5 years
Average volatility	70.00%	64.00%	73.00%	55.00%
Risk-free interest rate	2.86%	1.73%	2.67%	1.83%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Nonemployees [Member]
Expected term (Year)	10 years	10 years	10 years	10 years
Average volatility	66.00%	78.00%	66.00%	78.00%
Risk-free interest rate	3.04%	2.32%	3.04%	2.31%
Dividend yield	0.00%	0.00%	0.00%	0.00%

Note 9 - Summary of Stock Opt_8

Note 9 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock-based compensation expense	$ 765	$ 487	$ 2,294	$ 1,314
Cost of Sales [Member]
Stock-based compensation expense	19	5	47	12
Research and Development Expense [Member]
Stock-based compensation expense	79	62	266	170
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 667	$ 420	$ 1,981	$ 1,132

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2018
Income Tax Expense (Benefit), Total			$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%	0.00%	0.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent, Total					0.00%

Note 11 - Related Party Trans_2

Note 11 - Related Party Transactions (Details Textual) - USD ($)	Aug. 08, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Dec. 31, 2017
Payments to Acquire Equity Method Investments					$ 2,500,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Payments to Acquire Equity Method Investments	$ 2,500,000			2,500,000
Stellartech Research Corporation [Member]
Stock Issued During Period, Shares, New Issues						37,500
Related Party Transaction, Amounts of Transaction		$ 3,015,000	$ 2,620,000	8,613,000	$ 6,326,000
Accounts Payable, Related Parties, Current		1,162,000		1,162,000		$ 1,162,000	$ 1,380,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Related Party Transaction, Amounts of Transaction		81,000		224,000
Accounts Payable, Related Parties, Current		$ 27,000		$ 27,000		$ 27,000	$ 28,000